Posted by Michael Wonder on 16 Apr 2026
Arbutus receives US FDA fast track designation for imdusiran for the treatment of chronic hepatitis B
15 April 2026 - Arbutus Biopharma today announced that the US FDA has granted fast track designation for imdusiran for the treatment of chronic hepatitis B.
Imdusiran is an RNAi therapeutic specifically designed to reduce all hepatitis B viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to control the virus.
